Opendata, web and dolomites

HYPERQTOTAL

“Diagnosis of Ischemic Heart Disease by means of innovative and highly accurate high frequency QRS electrocardiogram analysis”

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "HYPERQTOTAL" data sheet

The following table provides information about the project.

Coordinator
BSP BIOLOGICAL SIGNAL PROCESSING LTD 

Organization address
address: 22A WALLENBERG ST
city: TEL AVIV
postcode: 69719
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://bsp.co.il/ Email
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BSP BIOLOGICAL SIGNAL PROCESSING LTD IL (TEL AVIV) coordinator 50˙000.00

Map

 Project objective

Occlusion of the coronary arteries that supply oxygenated blood to the heart muscle is referred to as ischemic heart disease (IHD). IHD is the most common, serious, chronic, life-threatening illness in the developed world. Currently, the most widely used tool for diagnosing IHD is the electrocardiogram (ECG), which records the electrical activity of the cardiac muscle as it generates the stages of the cardiac cycle. Specific changes in the ECG recorded during physical stress protocols are used for the non-invasive detection of IHD. Patients with positive stress test results are usually referred for further investigation. However, the sensitivity of the standard ECG, even during stress tests, is relatively poor, and is generally considered to be between 50% and 70%, and in some studies has been reported to be even lower. That, in other words, means that 30-50% of all IHD patients are not diagnosed correctly by standard stress ECGs. Traditional ECG analysis is performed in the 0.05 – 100Hz frequency range. However, a significant body of evidence accumulated during recent years indicates that higher frequency spectral components of the ECG signal contain valuable information for the detection of IHD. Studies published by Prof. Shimon Abboud, BSP’s chief scientist, and Dr. Amir Beker, BSP’s founder and CEO, have shown that the presence of ischemic pathologies in the heart is highly correlated with specific changes in the high-frequency spectral components of the ECG. BSP has pioneered the clinical implementation of high-frequency ECG and has developed it into a valuable diagnostic application. The company’s proprietary HyperQ™ technology extracts and analyses the high-frequency components of the ECG. BSP has pursued the development of its HyperQ™ technology in two parallel, highly correlated, pathways: (a) acquisition and reliable production of the HyperQ™ signal, and (b) analysis of the HyperQ™ signal for extracting clinical and diagnostic information.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPERQTOTAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPERQTOTAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More